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Introduction
Across the world, diabetes mellitus has been one of the important 
diseases for its various impact to medical and social aspects1 The 
prevalence is now increasing more in developing and developed 
countries. Diabetic state has to be controlled in order to protect several 
chronic complications.2 They include macrovascular angiopathy such 
as brain, heart, foot, microvascular angiopathy such as neuropathy, 
retinopathy and nephropathy, as well as increased cancer risk (relative 
ratio: 1.19/1.27 in M/F).2,3 There have been three kinds of principles 
for the therapy of the diabetes. They are i) adequate diet therapy, ii) 
aerobic exercise therapy, and iii) pharmacotherapy including oral 
hyperglycemic agents (OHAs) and injection method for diabetes.4
 Regarding the diet therapy, current topics include the gradual 
changes from calorie restriction (CR) to low carbohydrate diet 
(LCD). Formerly, LCD was initiated by Atkins, Bernstein and others 
in medical and health fields.5 The trend was gradually known and 
prevalent in North American and European area. Further, several 
reports comparing the effects among CR, LCD and Mediterranean 
diet have been on discussion.6 LCD has been evaluated as more 
effective method for metabolic syndrome including obesity, diabetes 
and so on.7 Successively, some discussion has been found concerning 
the definition of several types of LCD nowadays.8 
 On the other hand, the authors and collaborators have started LCD 
at first in Japan.9 We have continued developing LCD movement 
through Japan LCD promotion association (JLCDPA).10 For diabetic 
research, we have reported several papers on LCD, comparison of LCD 
and CR, blood glucose profiles, increased ketone bodies, continuous 
glucose monitoring (CGM), meal tolerance test (MTT), and others.11 
Furthermore, various reports about diabetic complications have been 
presented so far.12,13 Recent topics for medication include new agents 
such as Dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like 
peptide-1 receptor agonist (GLP-1 RA). 
Among our clinical practice, we experienced an impressive 
female diabetic patient. She has various medical problems, diabetic 
complications, continuous intake of steroid for years and has 
remarkable effect to new injection agentXultophy® including both of 
insulin and GLP-1 RA. General clinical course of the case and some 
discussion are described in this article.
Case report
Present history
The case was 79-year-old female patient with multiple kinds 
of diseases. Originally, she has been obese from 45 years old, and 
suffered from bronchial asthma and chronic obstructive pulmonary 
disease (COPD) from 56 years old. The asthmatic attack was rather 
frequent, then she was provided steroids for long. The dose was 
7.5-10mg/day of prednisolone and other agents of theophylline was 
also continued. Furthermore, she showed several symptoms of sleep 
apnea syndrome (SAS) from 75 years. Then she has been treated for 
Continuous Positive Airway Pressure (CPAP) at night for 4 years. Her 
physique had been 145cm, 62-65kg, BMI 29.5- 30.9.
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Abstract
Diabetes mellitus causes macrovascular, microvascular angiopathy, and increased cancer 
risk. Authors et al. have continued clinical practice and research on diabetes cases. 
Current case is impressive 79-year-old female with various diseases. They include asthma 
and COPD, steroid intake for years, sleep apnea syndrome (SAS), Continuous Positive 
Airway Pressure (CPAP) therapy, tongue cancer, arteriosclerosis, bone complications, 
Carpal tunnel syndrome (CTS), and so on. When she developed hyperglycemia with 9.0% 
of HbA1c, Xultophy® was started. It contains insulin degludec and liraglutide which is 
Glucagon-like peptide-1 receptor agonist (GLP-1 RA). HbA1c values decreased as 7.9%, 
7.3%, 6.9%, 6.5% in 1-4 months, with remarkable effect. The satisfactory efficacy may be 
from double agents of Xultophy® or probable secondary diabetes due to continuation of 
steroid of the case. This report will be expected to be some reference in the future diabetic 
research development.
Keywords: Xultophy®, glucagon-like peptide-1 receptor agonist (GLP-1 RA), Japan 
LCD promotion association (JLCDPA), Carpal tunnel syndrome (CTS), oral hyperglycemic 
agents (OHAs)
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Sound levels in movie theaters: is there a potential for hearing loss?
For last few years, she has suffered from additional several 
diseases. She fell and had a left medial femoral detachment fracture 
on May 2018. At that time, her value of young adult mean (YAM) 
was 75% with rather decreased bone mineral density (BMD), and she 
was diagnosed as osteopenia. She was started to be given Ibandronate 
sodium hydrate (Bonviva Syringes®, ATC code: M05BA06) once per 
month. 
She developed discomfort in the oral cavity and tongue in October, 
2018. Further evaluation revealed that she had a tongue cancer.
Then, she had an operation for finger-tip sized tumor, which was 
successfully performed in December, 2018. She fell again in January 
2019. She was diagnosed to have a left femoral neck fracture, atrial 
fibrillation (Af), hypertension and previous cerebral vascular accident 
(CVA). Then she was provided the operation of the femoral bone and 
the administration of anti-coagulant agents.
After that, she had felt the numbness and diminished grip strength 
in her left hand. She was diagnosed as left median nerve palsy (Carpal 
tunnel syndrome, CTS), and had the operationin May, 2019.After the 
operation, her HbA1c was followed up, which was 7.0% in July. Then 
she was started to have DPP-4 inhibitor teneligliptin hydrobromide 
hydrate (Tenelia®). 
However, HbA1c was exacerbated to 7.6% in September, and 9.0% 
in December. Consequently, she was started to have Xultophy®, which 
has both of insulin degludec and liraglutide (xultophy® 100/3.6) Pen. 
Standard dose is usually 10 dose/ one injection, including degludec 10 
units and liraglutide 0.36 mg. In this case 5 dose was injected once per 
day. Her body weight was 66kg in December.
 Consequently, the HbA1c value has been reduced as followed: 
7.9% in January, 7.3% in February, 6.9% in March and 6.5% in April, 
2020. At that time, her weight was 64kg. Summarized these situations 
above, Figure 1 showed the clinical course of history, HbA1c value 
and several kinds of treatments. 
Figure 1 Clinical course of various episodes, treatments and the changes in HbA1c value. 
Physical examination
Her physicals on September 2019 were as follows: consciousness 
was alert, the vitals were pulse 80/min, BP 140/86mmHg, SpO2 
97%, BT 36.7Co, respiration was normal, body stature 145cm, body 
weight 64kg, Body Mass Index (BMI) 30.4kg/m2. Lung sound was 
a little harsh, heart showed no significant murmurs, abdomen is 
unremarkable. She showed negative neurological abnormalities. 
Several examination
Laboratory exams were performed on September 2019. CBC 
showed that RBC 4.49x106/μL, Hb11.5g/dL, WBC 9500/μL, Plt 
27.3x104/μL, Biochemistry showed that TP 6.6g/dL, Alb 4.0g/dL, 
BUN 24mg/dL, Cre 0.9mg/dL, eGFR 43mL/min, T-Bil 0.4mg/dL, 
AST 21U/L, ALT 20U/L, ALP 138 U/L (100-340), LDH 244U/L 
(110-210), CK 124U/L (30-150), C-reactive Protein (CRP) 0.08mg/
dL, blood glucose 187mg/dL, HbA1c 7.6%.
She had basal screening examinations. Chest X-ray showed a little 
emphysematous change and electrocardiogram (ECG) revealed atrial 
fibrillation (Af). Abdominal X-ray was negative and abdominal CT 
scan showed moderate fatty liver. Urinalysis showed that protein 
(-), glucose (+), urobilinogen (+/-). She has showed unremarkable 
findings in retinopathy, neuropathy and nephropathy. 
Problem lists
#1 Obesity (45 years old)
#2 Bronchial asthma and COPD (56 yo)
#3 continuation of prednisolone (56 yo)
#4 CPAP treatment (75 yo) 
#5 tongue cancer (77 yo)
#6 atrial fibrillation (Af), hypertension (77 yo)
#7 previous CVA(77 yo)
#8 osteopenia and bone fracture (77 yo)
#9 Carpal tunnel syndrome (CTS) (78 yo)
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#10 Diabetic state (79 yo)
#11 administration of Xultophy® (79 yo)
Treatment of problems
According to the problems mentioned above, treatments of these 
problems are summarized as follows.
i. Asthma, COPD and CPAP (#2-4): ambroxol hydrochloride 
(Mucosolvan L®) 45mg/day as an Airway lubricant, 
prednisolone (Predonine®) 10mg/day as steroids (#3), 
theophylline (Theolong®) 400mg/day as a Xanthine derivative, 
and fluticasone propionate 50μg and formoterol fumarate 
hydrate 5μg (Flutiform Aerosol®)x2 doses/day as long acting 
beta 2 stimulator. CPAP has been continued for 4 years (#4).
ii. Af and hypertension (#6): rivaroxaban (Lixiana®) 30 mg/day 
as a direct oral anticoagulant (DOAC), verapamil hydrochloride 
(Vasolan®) 240mg/day as a Ca blocker (class IV) and 
spironolactone (Aldactone-A®) 25mg/day
iii. previous CVA (#7):rivaroxaban (Lixiana®) 30mg/day as a direct 
oral anticoagulant (DOAC)
iv. osteopenia and bone fracture(#8): Ibandronate sodium hydrate 
(Bonviva Syringes®)
v. Diabetes and Xultophay® (#10,11):teneligliptin hydrobromide 
hydrate (Tenelia®) 20mg/day, as DPP-4 inhibitor and 
Xultophay® including both of insulin degludec and liraglutide 
(xultophy®100/3.6) Pen. In this case 5 dose was injected once 
per day, which includes degludec 5 units and liraglutide 0.18 mg.
Discussion
In this report, the case associated with a variety of medical 
problems was described. These problems are discussed in the order of 
the medical problems in the following. As the underlying diseases, the 
case had bronchial asthma and COPD (#2). For this treatment, steroid 
therapy was indispensable because theophylline treatment alone was 
not effective (#3). The continuation of steroid for years may have 
involved other medical problems.
Regarding CPAP (#4), it was started four years ago because of the 
presence of Obesity and COPD (#1, #2). CPAP situation seemed to 
be stable as a result of the investigation. CPAP report was shown as 
follows: PAP mean pressure of 8.1cm H2O, a maximum PAP pressure 
of 9.3cm H2O, a mean large leak of 2 minutes 18 seconds and an apnea 
hypopnea index (AHI) of 1.2.
The case had tongue cancer in the category of Oral squamous 
cell carcinoma (OSCC)(#5). OSCC has been most frequently found 
in tongue, neck and head region.14 There was an experimental 
steroidogenic model for OSCC in translational research. As a result, 
the development of the target and gene of OSCC would be involved 
in various influencing factors such as Cancer Stem Cells (CSCs), 
Endothelial Growth Factor Receptor (EGFR), Progesterone Receptor 
(PR) and Estrogen Receptor (ER).14
From previous studies, diabetes seems to promote the activation 
of the Ras/Raf/MAPK signal transduction pathway.15 It is mainly 
induced by erbB2 and erbB3 receptors, which leads to stimulating 
cell proliferation.
About a year ago, Af, hypertension and previous CVA have been 
pointed out (#6, #7). Her medical history shows that those were 
not found before. It may be suggested from the development of 
arteriosclerosis such as worsening of obesity, potential progress for 
high blood pressure and high blood glucose.
 The case showed osteopenia with 75% of young adult mean 
(YAM) value (#8). According to the standard guideline, the bone 
mineral density (BMD) was classified as normal in 80% or more of 
YAM, 70%-80% as osteopenia, and less than 70% as osteoporosis.16
Later the case developed fractures of the femur. These onsets 
may be involved in several factors, such as obesity (# 1), long-term 
administration of steroids (#3), postmenopausal female hormone 
decline, and others. Regarding the risk of the relationship between hip 
fracture (#8) and use of oral corticosteroid, there was a case-control 
study. For 14 years, cases with hip fracture (n=4538) were compared 
with cases without fracture (n=4538). As a result, the odds ratio (OR) 
was proved to be 1.17.17
Carpal tunnel syndrome (CTS) has been a common medical 
problem (#9), which remains most frequently reported from median 
nerve compression. Their risk factors may include obesity, pregnancy, 
monotonous wrist activity, rheumatoid inflammation, genetic 
heredity, and so on.18 In current case, she has obesity and diabetes 
as fundamental diseases. For diabetic cases, the incidence of carpal 
tunnel syndrome has been 14% for those without diabetes, and 
30% for those with diabetic neuropathy.18 On the other hand, during 
pregnancy it would be reduced to about 2% in prevalence rate.19
There was a meta-analysis concerning the relationship between 
diabetes and CTS.20 From studies from 1950 to 2015, 25 studies with 
92564 cases were investigated. The estimated OR was 1.97 (95% CI 
1.56–2.49) for unadjusted situation and 1.69 (95% CI 1.45–1.96) for 
controlling potential confounders. The results do not differ between 
type 1 and type 2.20 
The case showed hyperglycemia, and rapid improvement of 
diabetic state after starting Xultophy(#10, #11). There are two current 
standard guidelines for diabetes, which are the American Diabetes 
Association (ADA) Standards of Medical Care in Diabetes 202021 
and the 2019 “Consensus Statement by the American Association 
of Clinical Endocrinologists (AACE) and American College of 
Endocrinology (ACE) on the Comprehensive Type 2 Diabetes 
Management Algorithm”.22 Both guidelines have recommended 
physicians to consider the combination of injection treatment for post-
prandial hyperglycemia in the cases who show basal insulin doses 
0.5units/kg/day with higher HbA1c level.21 
Xultophy® includes insulin and Glucagon-like peptide-1 receptor 
agonist (GLP-1 RA). When Xultophy® (100/3.6) is injected, 1 unit 
contains 1 unit of insulin degludec and 0.036mg of liraglutide.23 It 
can be injected from 10-50 units. The Xultophy® pen is prefilled by 
300 units of Xultophy® 100/3.6 (300 units insulin degludec/10.8mg 
liraglutide). It has no push-button extension, and the dose button does 
not extend while dialing the amount, no matter how the dose is.23 It 
has once-daily regimen, and shows less hypoglycemia or weight gain 
compared with intensive insulin regimens. Furthermore, it shows 
reduced gastrointestinal (GI) adverse effects compared with GLP-1 
RA alone.23,24
In this case, administration of Xultophy brought a sharp decrease 
in HbA1c, and clinical remarkable effect was observed. One of the 
reasons is that it would be secondary diabetes due to taking steroids 
for many years. Therefore, the function ability of insulin secretion 
may be not so exhausted. However, all of endocrinological evaluation 
in detail was not been performed yet at this time.
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Current study has some limitations. A variety of medical problems 
were found in this case. It may be related to taking steroids for 
years, but all pathophysiological studies have not been conducted. 
For diabetes, it is planned to check C-peptide values in blood and 
urine, diurnal blood glucose fluctuation, reactivity to glucose loading, 
associated with current data of obesity, hypertension, dyslipidemia, 
uric acid, and so on.
In summary, this case seemed to be impressive from several points 
of view. They include asthma and COPD, CPAP therapy, tongue 
cancer, arteriosclerosis, bone complications, CTS and administration 
of Xultophy®. Many years of steroid administration may be influenced 
the progress. We hope that this report will serve as a reference for 
future diabetes practice. 
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